Bernstein analyst Eve Burstein has maintained their bullish stance on TMO stock, giving a Buy rating on September 24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eve Burstein has given her Buy rating due to a combination of factors that highlight Thermo Fisher’s strong performance and growth potential. The company has demonstrated significant outperformance in recent months, with a notable increase in stock value compared to the broader market. This performance is underpinned by conservative yet achievable growth targets, with organic growth expected to surpass market averages due to Thermo Fisher’s effective cross-selling capabilities.
Moreover, concerns about margin expansion have been addressed, as the company’s growth in certain business areas is not expected to negatively impact long-term margin goals. While large-scale mergers and acquisitions may be limited, smaller strategic acquisitions can still support earnings per share targets. Additionally, the current valuation of Thermo Fisher is seen as justified, with potential for further upside due to conservative estimates and capital deployment strategies. Overall, despite recent stock gains, Burstein believes that Thermo Fisher remains a strong investment opportunity with a promising outlook.
Burstein covers the Healthcare sector, focusing on stocks such as Thermo Fisher, Waters, and Pacific Biosciences. According to TipRanks, Burstein has an average return of 3.0% and a 48.65% success rate on recommended stocks.
In another report released on September 24, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $521.00 price target.